It is NBE-Therapeutics’ vision to become an internationally recognized leader and pioneer for the development of innovative and effective antibody-based medicines. The main focus will be on the development of next-generation Antibody Drug Conjugate (ADCs) products for the treatment of cancer.
In order to achieve this, NBE Therapeutics has developed potent antibody discovery and enzymatic, site-specific toxin-antibody conjugation technologies and plans to utilize these pioneering technologies for the development of a robust therapeutic antibody and ADC drug pipeline.
Value adding collaborations and product licensing will be pursued throughout every stage of company development.
- Basel, 2017-11-28 - NBE-Therapeutics appoints Dr. Nicole Onetto to its Board of Directors
- Lisbon, Portugal, 2017-11-14 - NBE-Therapeutics presented update on R&D activities at 2017-PEGS conference
- Basel, Switzerland, 2017-11-02 - NBE-Therapeutics presented update on R&D activities at 2017 HPAPI World Congress